Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.45 |
| ▸ | NMT2 | O60551 | 2/20 | 0.43 |
| ▸ | NMT1 | P30419 | 2/20 | 0.43 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24276030 | 1.00 | NOD1 (0.45) | NOD1NMT2NMT1GLP1RGLO1 | |
| SCHEMBL20215722 | 0.94 | NOD1 (0.50) | NOD1NMT2NMT1GLP1RGLO1 | |
| SCHEMBL20375263 | 0.89 | NOD1 (0.47) | NOD1NMT2NMT1GLP1RGLO1 | |
| SCHEMBL21418066 | 0.89 | NOD1 (0.47) | NOD1NMT2NMT1GLP1RGLO1 | |
| SCHEMBL25849917 | 0.89 | NOD1 (0.56) | NOD1GLP1R | |
| SCHEMBL14167356 | 0.86 | NOD1 (0.50) | NOD1NMT2NMT1GLP1RGLO1 | |
| SCHEMBL16156102 | 0.84 | NOD1 (0.49) | NOD1NMT2NMT1GLP1RGLO1 | |
| SCHEMBL16156108 | 0.84 | NOD1 (0.49) | NOD1NMT2NMT1GLP1RGLO1 | |
| SCHEMBL19867141 | 0.84 | GLP1R (0.47) | NOD1NMT2NMT1GLP1RGLO1 | |
| SCHEMBL14783928 | 0.84 | NOD1 (0.48) | NOD1NMT2NMT1GLP1RGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813312-B2 | Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11813312-B2 | Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11091528-B2 | Acylated glucagon analogues | ZEALAND PHARMA A/S (DK) | 2021-08-17 | — | — | US | disclosed |
| US-11008375-B2 | GIP-GLP-1 dual agonist compounds and methods | ZEALAND PHARMA A/S (DK) | 2021-05-18 | — | — | US | disclosed |
| US-20200157168-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2020-05-21 | — | — | US | disclosed |
| US-10457714-B2 | Acylated glucagon analogues | ZEALAND PHARMA A/S (DK) | 2019-10-29 | — | — | US | disclosed |
| US-20190218270-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2019-07-18 | — | — | US | disclosed |
| US-10336802-B2 | Acylated glucagon analogue | ZEALAND PHARMA A/S (DK) | 2019-07-02 | — | — | US | disclosed |
| US-20180141990-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2018-05-24 | — | — | US | disclosed |
| US-20180094038-A1 | ACYLATED GLUCAGON ANALOGUE | ZEALAND PHARMA A/S (DK) | 2018-04-05 | — | — | US | disclosed |
| US-9896495-B2 | Acylated glucagon analogues | ZEALAND PHARMA A/S (DK) | 2018-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457714-B2 | Acylated glucagon analogues | GLP1R, GCGR, GIPR | NOD1 1448/4885NMT2 325/4885NMT1 304/4885 |
| US-11813312-B2 | Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis | GLP1R, GCGR, GIPR | NOD1 693/4885NMT2 319/4885NMT1 343/4885 |
| US-20180141990-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | NOD1 1448/4885NMT2 325/4885NMT1 304/4885 |
| US-20190218270-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | GLP1R, GIPR, GCGR | NOD1 2661/4885NMT2 541/4885NMT1 629/4885 |
| US-20180094038-A1 | ACYLATED GLUCAGON ANALOGUE | GLP1R, GCGR, GIPR | NOD1 1250/4885NMT2 304/4885NMT1 282/4885 |
| US-10336802-B2 | Acylated glucagon analogue | GLP1R, GCGR, GIPR | NOD1 1213/4885NMT2 313/4885NMT1 280/4885 |
| US-11091528-B2 | Acylated glucagon analogues | GLP1R, GCGR, GIPR | NOD1 1448/4885NMT2 325/4885NMT1 304/4885 |
| US-11008375-B2 | GIP-GLP-1 dual agonist compounds and methods | GLP1R, GIPR, GCGR | NOD1 2661/4885NMT2 541/4885NMT1 629/4885 |
| US-20200157168-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | NOD1 1448/4885NMT2 325/4885NMT1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.